Mr. Speaker, I wish to assure you and the member opposite that we are also committed to doing the right thing. The thalidomide survivors contribution program is designed to support Canadian thalidomide survivors who have suffered a range of disabilities, significantly impacting their quality of life.
In programs such as the thalidomide survivors contribution program, it is important that eligibility assessments be done properly in order to reduce the risk of wrongfully attributing a person's condition. Some conditions which resemble thalidomide, but are not caused by thalidomide, can be transmitted to future generations. It is important for those individuals to obtain the right medical care and treatment.
As I had earlier stated, 25 additional individuals have been recognized as confirmed survivors. This shows that the criteria have produced some positive results. Furthermore, information gathered at the end of fiscal year 2016-17 indicated that 80% of confirmed survivors said that the thalidomide survivors contribution program was helping them age with dignity. This demonstrates that the program is achieving its intended impact.
I would ask for the House's patience while the government concludes its assessment of the recommendations made by the health committee. We will report back to the House as soon as that important work is completed.